Cargando…
Is tenofovir and entecavir combination therapy still the optimal treatment for chronic hepatitis B patients with prior suboptimal response?
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
The Korean Association for the Study of the Liver
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7364356/ https://www.ncbi.nlm.nih.gov/pubmed/32646206 http://dx.doi.org/10.3350/cmh.2020.0099 |
| _version_ | 1783559818710089728 |
|---|---|
| author | Jang, Byoung Kuk |
| author_facet | Jang, Byoung Kuk |
| author_sort | Jang, Byoung Kuk |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7364356 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | The Korean Association for the Study of the Liver |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-73643562020-07-27 Is tenofovir and entecavir combination therapy still the optimal treatment for chronic hepatitis B patients with prior suboptimal response? Jang, Byoung Kuk Clin Mol Hepatol Editorial The Korean Association for the Study of the Liver 2020-07 2020-07-01 /pmc/articles/PMC7364356/ /pubmed/32646206 http://dx.doi.org/10.3350/cmh.2020.0099 Text en Copyright © 2020 by The Korean Association for the Study of the Liver This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Editorial Jang, Byoung Kuk Is tenofovir and entecavir combination therapy still the optimal treatment for chronic hepatitis B patients with prior suboptimal response? |
| title | Is tenofovir and entecavir combination therapy still the optimal treatment for chronic hepatitis B patients with prior suboptimal response? |
| title_full | Is tenofovir and entecavir combination therapy still the optimal treatment for chronic hepatitis B patients with prior suboptimal response? |
| title_fullStr | Is tenofovir and entecavir combination therapy still the optimal treatment for chronic hepatitis B patients with prior suboptimal response? |
| title_full_unstemmed | Is tenofovir and entecavir combination therapy still the optimal treatment for chronic hepatitis B patients with prior suboptimal response? |
| title_short | Is tenofovir and entecavir combination therapy still the optimal treatment for chronic hepatitis B patients with prior suboptimal response? |
| title_sort | is tenofovir and entecavir combination therapy still the optimal treatment for chronic hepatitis b patients with prior suboptimal response? |
| topic | Editorial |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7364356/ https://www.ncbi.nlm.nih.gov/pubmed/32646206 http://dx.doi.org/10.3350/cmh.2020.0099 |
| work_keys_str_mv | AT jangbyoungkuk istenofovirandentecavircombinationtherapystilltheoptimaltreatmentforchronichepatitisbpatientswithpriorsuboptimalresponse |